Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 3/20 | 0.48 |
| ▸ | NMT1 | P30419 | 2/20 | 0.47 |
| ▸ | PPM1D | O15297 | 2/20 | 0.47 |
| ▸ | FNTA | P49354 | 2/20 | 0.47 |
| ▸ | FNTB | P49356 | 2/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | TAF1 | P21675 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | NR1D2 | Q14995 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725438 | 0.88 | MEN1 (0.50) | — | |
| SCHEMBL1364691 | 0.86 | NMT1 (0.52) | NMT1HDAC1 | |
| SCHEMBL12725436 | 0.79 | CHRM3 (0.74) | CHRM3 | |
| SCHEMBL13162660 | 0.77 | LOXL2 (0.54) | PPM1D | |
| SCHEMBL1363925 | 0.74 | NMT1 (0.51) | NMT1TAF1NR1D2 | |
| SCHEMBL3434754 | 0.74 | NMT1 (0.51) | NMT1TAF1NR1D2 | |
| SCHEMBL16033312 | 0.73 | HTR1A (0.46) | — | |
| SCHEMBL12725442 | 0.73 | CHRM3 (0.56) | CHRM3 | |
| SCHEMBL9005670 | 0.72 | PPM1D (0.64) | PPM1D | |
| SCHEMBL9005566 | 0.72 | PPM1D (0.64) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067408-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-11-29 | — | — | US | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | MEP1B 1467/4885NMT1 1261/4885PPM1D 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.